Key Insights

Highlights

Success Rate

89% trial completion (above average)

Published Results

28 trials with published results (18%)

Research Maturity

80 completed trials (52% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

6.5%

10 terminated out of 154 trials

Success Rate

88.9%

+2.4% vs benchmark

Late-Stage Pipeline

11%

17 trials in Phase 3/4

Results Transparency

35%

28 of 80 completed with results

Key Signals

28 with results89% success

Data Visualizations

Phase Distribution

120Total
Not Applicable (70)
Early P 1 (1)
P 1 (12)
P 2 (20)
P 3 (9)
P 4 (8)

Trial Status

Completed80
Recruiting31
Unknown16
Terminated10
Not Yet Recruiting8
Active Not Recruiting5

Trial Success Rate

88.9%

Benchmark: 86.5%

Based on 80 completed trials

Clinical Trials (154)

Showing 20 of 20 trials
NCT07326566Phase 2Recruiting

Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII

NCT06088121Not ApplicableRecruiting

Study to Evaluate the Efficacy and Safety of ATNC-MDD V1(TMS With Cognitive Training) in Mild Alzheimer's Dementia

NCT06249776Not ApplicableCompleted

Gravity Stent-Retriever System For Reperfusion Of Large Vessel Occlusion Stroke Trial

NCT03911388Phase 1Recruiting

HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors

NCT05508789Phase 3Recruiting

A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)

NCT05318976Phase 2Completed

A Study of XPro1595 in Patients With Early Alzheimer's Disease With Biomarkers of Inflammation

NCT05903235Not ApplicableRecruiting

Mixed Reality and Virtual Reality Technology With Mirror Therapy for Stroke Rehabilitation

NCT03678194Not ApplicableRecruiting

Treating Depression on a Day-to-day Basis: Development of a Tool for Physicians Based on a Smartphone Application

NCT07451769Not ApplicableNot Yet Recruiting

Selective Activation of the Adrenomedullin Receptors in Migraine

NCT05522387Phase 2Terminated

An Open-Label Extension of XPro1595 in Patients With Alzheimer's Disease

NCT05386108Phase 1Recruiting

Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer

NCT07324330Not ApplicableRecruiting

Slowing Cognitive Decline in Alpha-synucleinopathies by Enhancing Physical Activity

NCT07340775Not ApplicableNot Yet Recruiting

Hypersensitivity to Amylin in Post-Traumatic Headache

NCT07340788Not ApplicableNot Yet Recruiting

Amylin-Induced Migraine Attacks Without Aura

NCT07335185Not ApplicableNot Yet Recruiting

Gravity Stroke System for Recanalization of Large Vessel Occlusion Strokes

NCT07313098Not Yet Recruiting

Longitudinal Assessment of Protein Markers in the Cerebrospinal Fluid of Patients With Central Nervous System Involvement

NCT07288385Not ApplicableRecruiting

Investigating the Feasibility of Combining Virtual Reality and Bilateral Transcranial Direct Stimulation to Improve Upper Limb Recovery in Patients With Stroke

NCT06954610Recruiting

Cardiac Assessment for Recurrent Stroke Risk Evaluation in Atrial Fibrillation

NCT05738486Phase 3Active Not Recruiting

A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6)

NCT05590884Phase 2CompletedPrimary

Gadopiclenol Pharmacokinetics, Safety and Efficacy in Children < 2 Years of Age

Scroll to load more

Research Network

Activity Timeline